1. Home
  2. LIF vs ACAD Comparison

LIF vs ACAD Comparison

Compare LIF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Life360 Inc.

LIF

Life360 Inc.

HOLD

Current Price

$53.97

Market Cap

4.2B

Sector

N/A

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$23.64

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIF
ACAD
Founded
2008
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.4B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
LIF
ACAD
Price
$53.97
$23.64
Analyst Decision
Strong Buy
Buy
Analyst Count
8
22
Target Price
$89.64
$29.95
AVG Volume (30 Days)
1.2M
1.3M
Earning Date
03-02-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
0.12
1.54
Revenue
$459,031,000.00
$1,047,118,000.00
Revenue This Year
$31.03
$15.16
Revenue Next Year
$31.66
$11.24
P/E Ratio
$141.66
$15.29
Revenue Growth
33.86
12.69
52 Week Low
$29.62
$13.40
52 Week High
$112.54
$28.35

Technical Indicators

Market Signals
Indicator
LIF
ACAD
Relative Strength Index (RSI) 39.95 36.27
Support Level $52.22 $23.37
Resistance Level $61.58 $26.23
Average True Range (ATR) 2.86 1.02
MACD -0.29 -0.34
Stochastic Oscillator 13.07 9.68

Price Performance

Historical Comparison
LIF
ACAD

About LIF Life360 Inc.

Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: